Previous
Pause
Next
Skip to Navigation
↓
Publications
Year
Year
Year
-Year
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Researcher
- Any -
Afif
dyllanes
gemmula
juampe
usuario_prueba
Almeida e Silva, Filomena Augusta
Angás Pajas, Jorge
Arenal , Raúl
Baptista , Pedro Miguel
Bernechea Navarro, María
Bover Arbós, Pere
Calvo Lacosta, Jorge Hugo
Carstensen , Hans-Heinrich
Cazcarro Castellano, Ignacio
Cobarrubias Baglietto, Sebastián Felipe
Espina Cadena, Laura
Fernandez Antoran, David
Gil Hernández, Vanesa
Gracia Lostao, Ana Isabel
Gurauskis , Jonas
Gómez Candón, David
Hernández Ainsa, Silvia
Hernández Latas, José Antonio
Hurtado Guerrero, Ramón
Jiménez Schuhmacher, Alberto
Juarez-Perez , Emilio J.
Köhler , Ralf
Lopes de Sousa Martins, Pedro Alexandre
Martín Yebra, Alba
Martínez Delgado, David
Millán Gasca, Javier
Montiel , Manuel
Muñoz Soro, José Félix
Olmo , Jose
Ordovás Vidal, Laura
Philippidis , George
Ramón García, Santiago
Roque , Carla
Schoorlemmer , Jon
Sola , Daniel
Stavridis , Stelios
Sánchez Martínez, Diego
Velasco Lozano, Susana
Íñiguez Dieste, David
Title
Title
Year
Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains.
2013
Repurposing clinically approved cephalosporins for tuberculosis therapy.
2016
Targeting Tuberculosis: Existing drugs can - and should - be repurposed to fight neglected diseases.
2017
Targeting Tuberculosis: Existing drugs can – and should – be repurposed to fight neglected diseases.
2017
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening
2018
Sanfetrinem, repurposing an oral beta-lactam with intracellular activity for the treatment of tuberculosis
2019
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening
2019
The FICI paradigm: correcting flaws in antimicrobial in vitro synergy screens at their inception.
2019
Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency
2020
Repurposing Avermectins and Milbemycins against Mycobacteroides abscessus and Other Nontuberculous Mycobacteria
2021
Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial)
2022
The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme
2022
Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium
2023
In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae
2023
Repurposing β-Lactams for the Treatment of Mycobacterium kansasii Infections: An In Vitro Study
2023
Evaluation of critical parameters in the hollow-fibre system for tuberculosis: A case study of moxifloxacin
2024
Susceptibility testing of the live attenuated tuberculosis vaccine BCG and the vaccine candidate MTBVAC to currently WHO-recommended anti-tuberculosis drugs by the European committee on antimicrobial susceptibility testing (EUCAST) method
2024
The novel drug candidate VOMG kills Mycobacterium abscessus and other pathogens by inhibiting cell division
2024
Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans
2024